H-CYTE, Inc. announced the publication of new data supporting the safety and efficacy of its innovative autologous treatment in helping improve overall lung health. Published in the peer reviewed Journal of Regenerative Medicine & Biology Research, the observational study demonstrated statistically significant improvement in pulmonary function (FEV1% predicted) at 3 months and quality of life (CCQ) at 3-6, and 12 months post-treatment for GOLD stage 3 and 4 patients. The Institutional Review Board (IRB) approved study was conducted in 419 patients with chronic obstructive pulmonary disease (COPD). Results demonstrated 67% of participants treated with PRP-PBMC experienced either an improvement in their pulmonary lung function or no decline from baseline at 3 months with just one treatment. In addition, the study demonstrated statistically and clinically significant quality of life improvement. 83% of patients saw improvement at 3 months, 78% of patients at 6 months, and 73% of patients at 12 months post-treatment. Patients remained on any physician prescribed medications for their condition. The most common maintenance treatments for COPD include inhaled corticosteroids, beta-2 agonists, anticholinergics, nebulized albuterol and supplemental oxygen for the duration of the study. All participants tolerated the procedure well, and there were no reportable adverse or unexpected events. The data came from an externally validated patient database. The study design was observational following the intervention and therefore the limitations due to lack of a control group are recognized. To address this, a randomized, double-blind trial involving the company’s innovative PRP-PBMC therapy is currently being planned.